Radioactive Iodine (131I) Thyroid Ablation and the Salivary Glands

2022 ◽  
pp. 91-102
Author(s):  
Louis Mandel
1952 ◽  
Vol s3-93 (22) ◽  
pp. 133-146
Author(s):  
VERA FRETTER

If Helix aspersa, H. pomatia, Arion hortensis, and Agriolimax agrestis be fed on a diet which contains P32, autoradiographs show that the isotope is taken up by the digestive and lime cells of the digestive gland. From the formermost of it passes to the haemocoel, though some is retained for immediate metabolic activities; in the lime cells it is stored in calcium spherules. A very small amount of the tracer enters the body through the wall of the oesophagus, and more through the intestine, this site of diffusion being most pronounced directly after hibernation. The P33 in the haemocoel is dispersed to all tissues: all of them take up a little; in some it becomes concentrated. Concentrations appear in the nerve ring, the mucous and salivary glands, the odontophore and certain cells of the mantle. In the nervous system deposits are heavy around the fibres and slight in the cytoplasm of the cells; they indicate a compound, soluble in alcohol, which may be phospholipine, associated with medullated nerves. The phosphorus in mucous cells, most pronounced in the pedal and salivary glands, may be combined with the calcium which stabilizes mucus and prevents its rapid dispersal. The incorporation of isotope into the developing tooth of the radula indicates the relative activity of the basoblasts and cuspidoblasts: in early development of a tooth the basoblast secretes more actively, but as it becomes effete secretion by the cuspidoblast is accelerated. When the tooth is liberated from the latter there is no further addition to its substance. Phosphorus deposits in the mantle are in the calcium cells which secrete the shell. Here, as in the lime cells, and around certain blood-vessels, excess may be stored as calcium phosphate; reserves in the digestive gland are the largest. Amoebocytes concerned with the regeneration of the shell of Helix pomatia and H. aspersa carry the tracer element, and some of it is deposited in the shell. Also in the slug the tracer is transported by amoebocytes. Radioactive iodine in the lumen of the gut is taken up most readily by digestive cells; some enters the lime cells. Only in sparing quantities does this isotope pass from the gland to the rest of the body, and this entry is presumably associated with ionic exchange. It is not accumulated in any cell, except in the kidney whence it is excreted; it leaves the digestive cells to pass from the body with the faeces.


2019 ◽  
Vol 101 (5) ◽  
pp. e122-e124
Author(s):  
O Hamdy ◽  
S Raafat ◽  
GA Saleh ◽  
K Atallah ◽  
Mahmoud M Saleh ◽  
...  

Primary thyroid carcinoma after thyroid ablation by radioactive iodine is rare. We present a very rare condition of lateral apparent papillary thyroid carcinoma eight years after receiving radioactive iodine for thyrotoxicosis, which led to complete anatomical and functional involution of the thyroid gland.


2019 ◽  
Vol 59 (1) ◽  
pp. 99-109 ◽  
Author(s):  
Anery Patel ◽  
Elizabeth A. Kosmacek ◽  
Kurt W. Fisher ◽  
Whitney Goldner ◽  
Rebecca E. Oberley-Deegan

AbstractTreatment of differentiated thyroid cancer often involves administration of radioactive iodine (I-131) for remnant ablation or adjuvant therapy. However, there is morbidity associated with I-131 therapy, which can result in both acute and chronic complications. Currently, there are no approved radioprotectors that can be used in conjunction with I-131 to reduce complications in thyroid cancer therapy. It is well known that the damaging effects of ionizing radiation are mediated, in part, by the formation of reactive oxygen species (ROS). A potent scavenger of ROS, Mn(III)meso-tetrakis(N–n-butoxyethylpyridinium-2-yl)porphyrin (MnTnBuOE-2-PyP), has radioprotective and anti-tumor effects in various cancer models including head and neck, prostate, and brain tumors exposed to external beam radiation therapy. Female C57BL/6 mice were administered I-131 orally at doses of 0.0085–0.01 mCi/g (3.145 × 105 to 3.7 × 105 Bq) of body weight with or without MnTnBuOE-2-PyP. We measured acute external inflammation, blood cell counts, and collected thyroid tissue and salivary glands for histological examination. We found oral administration of I-131 caused an acute decrease in platelets and white blood cells, caused facial swelling, and loss of thyroid and salivary tissues. However, when MnTnBuOE-2-PyP was given during and after I-131 administration, blood cell counts remained in the normal range, less facial inflammation was observed, and the salivary glands were protected from radiation-induced killing. These data indicate that MnTnBuOE-2-PyP may be a potent radioprotector of salivary glands in thyroid cancer patients receiving I-131 therapy.


Sign in / Sign up

Export Citation Format

Share Document